Post-enrichment circulating tumor cell detection and enumeration via deformability impedance cytometry
Publication date: Available online 11 November 2019Source: Biosensors and BioelectronicsAuthor(s): Parham Ghassemi, Xiang Ren, Brittni M. Foster, Bethany A. Kerr, Masoud AgahAbstractCirculating tumor cells (CTCs) in blood can provide valuable information when detecting, diagnosing, and monitoring cancer. This paper describes a system that consists of a constriction-based microfluidic sensor with embedded electrodes that can detect and enumerate cancer cells in blood. The biosensor measures impedance in terms of magnitude and phase at multiple frequencies as cells transit through the constriction channel. Cancer cells deform as they move through while blood cells remain intact, thus generating differential impedance profiles that can be used for detecting and counting CTCs. Two versions of this device are reported, one where the electrodes are embedded into the disposable microfluidic channel, and the other in which the disposable chip is externally fixed to a reusable substrate housing the electrodes. Both configurations were tested by spiking breast or prostate cancer cells into murine blood, and both detected all tumor cells passing through the narrow channels while being able to differentiate between the two cell lines. The chip in its current format has a throughput of 1 μL/min. While the throughput is scalable by integrating more constriction channels in parallel, the presented assay is intended for post-enrichment label-free enumeration and characterization of CTCs...
Publication date: Available online 12 December 2019Source: European UrologyAuthor(s): Piotr Radziszewski, Waldemar Szabłoński
Publication date: Available online 12 December 2019Source: European UrologyAuthor(s): Yun Rose Li, Mack Roach
This study contributes with the discussion about the development of the molecular profiling of prostate cancer. The further development of similar studies could help in stratifying specific risk groups, leading to a more personalized therapeutic decision for prostate cancer treatment. PMID: 31826177 [PubMed - in process]
CONCLUSION: this evidence enhances and deepens the knowledge disclosed in the literature and contributes to the strengthening of nursing care actions when dealing with the sick. PMID: 31826165 [PubMed - in process]
Condition: Prostate Cancer Interventions: Radiation: Conventionally-fractionated WPRT; Radiation: Hypofractionated WPRT Sponsors: Lawson Health Research Institute; Canadian Association of Radiation Oncology; AbbVie Not yet recruiting
CONCLUSION: Primary Signet ring cell carcinoma of the prostate is a rare and aggressive histological variant of adenocarcinomas of the prostate. Treatment is the same as classical adenocarcinoma with an emphasis on aggressive multimodal treatment. PMID: 31823856 [PubMed - in process]
Authors: Yalcin S, Kaya E, Ebiloglu T, Akay S, Zor M, Sarıkaya S, Yilmaz S, Bedir S Abstract OBJECTIVES: In this research, we designed a cognitive fusion(CF) prostate biopsy(PB) (CFPB) technique by examining the multiparametric MRI of prostate (MP_MRI-P) images in a smart-phone near the trans-rectal ultrasound (TRUS) device, and examined the results. METHODS: Between January 2011 and January 2017, a total of 344 men who had PB enrolled in this study. Group 1 had a minimum of a 12-core standard TRUS PB (TRUSPB). Group 2 had CFPB while examining the MP_ MRI-P images in a smartphone near the TRUS device. A minimu...
Authors: Murray NP, Aedo S, Fuentealba C, Salazar A, Reyes E, Lopez MA, Minzer S Abstract INTRODUCTION: Minimal residual disease (MRD) is that which persists after curative treatment for prostate cancer. It has the potential to grow and cause metastasis. The detection of circulating prostate cells (CPCs) and bone marrow micro-metastasis could represent different sub-types of MRD. OBJECTIVE: To determine biochemical failure free survival and time to failure, the presence of circulating prostate cells and bone marrow micro-metastasis in men treated for low risk prostate cancer. HYPOTHESIS: The presence of MRD...
In conclusion, the present study demonstrated that PCAT19 negatively regulates the p53 tumor-suppression pathway, promoting cancer cell proliferation in patients with NSCLC. PMID: 31819778 [PubMed]
In conclusion, NKX3.1 shows routine expression in Sertoli cells and P501S shows routine expression in Leydig cells and rete testis epithelium. In addition, these markers can be positive in sex cord-stromal tumors and rete testis adenocarcinoma.